Should I buy or sell TFF Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TFFP shares. View TFFP analyst ratings or view top-rated stocks .

What is TFF Pharmaceuticals' stock price target for 2024?

1 brokers have issued 1-year price targets for TFF Pharmaceuticals' shares. Their TFFP share price targets range from $44.00 to $100.00. On average, they expect the company's share price to reach $72.00 in the next year. This suggests a possible upside of 2,049.3% from the stock's current price. View analysts price targets for TFFP or view top-rated stocks among Wall Street analysts .

How have TFFP shares performed in 2024?

TFF Pharmaceuticals' stock was trading at $7.02 at the beginning of the year. Since then, TFFP shares have decreased by 52.3% and is now trading at $3.35. View the best growth stocks for 2024 here .

Are investors shorting TFF Pharmaceuticals?

TFF Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 86,600 shares, an increase of 86.6% from the March 15th total of 46,400 shares. Based on an average trading volume of 28,500 shares, the days-to-cover ratio is presently 3.0 days. Approximately 3.4% of the shares of the stock are sold short. View TFF Pharmaceuticals' Short Interest .

When is TFF Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TFFP earnings forecast .

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) issued its quarterly earnings data on Tuesday, August, 15th. The company reported ($3.50) earnings per share for the quarter, topping analysts' consensus estimates of ($5.00) by $1.50. The business had revenue of $0.33 million for the quarter, compared to analysts' expectations of $0.10 million. TFF Pharmaceuticals had a negative net margin of 2,897.95% and a negative trailing twelve-month return on equity of 163.14%. During the same quarter in the prior year, the company earned ($8.50) earnings per share.

When did TFF Pharmaceuticals' stock split?

TFF Pharmaceuticals shares reverse split on Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC) , VBI Vaccines (VBIV) , Akero Therapeutics (AKRO) , VYNE Therapeutics (VYNE) , Acer Therapeutics (ACER) , Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Chiasma (CHMA) , Chimerix (CMRX) and DURECT (DRRX) .

When did TFF Pharmaceuticals IPO?

TFF Pharmaceuticals (TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at a price of $5.00 per share. National Securities acted as the underwriter for the IPO.

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TFFP

TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free TFFP Stock Alerts

$3.30

-0.22 (-6.25%)

(As of 03:02 PM ET)

Compare

Today's Range: $3.20
▼
$3.47
50-Day Range: $3.52
▼
$8.99
52-Week Range: $3.20
▼
$21.25

Volume: 25,644 shs
Average Volume: 28,288 shs
Market Capitalization: $8.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $72.00

Get TFF Pharmaceuticals alerts:

TFF Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,049.3% Upside
$72.00 Price Target
Short Interest: Healthy
3.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($7.28) to ($7.51) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
TFF Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
TFF Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.44% of the float of TFF Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
TFF Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TFF Pharmaceuticals has recently increased by 86.64%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TFF Pharmaceuticals does not currently pay a dividend.
Dividend Growth
TFF Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TFFP.

3.1

News and Social Media Coverage

News Sentiment
TFF Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for TFF Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
1 people have searched for TFFP on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added TFF Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TFF Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of TFF Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 15.25% of the stock of TFF Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for TFF Pharmaceuticals are expected to decrease in the coming year, from ($7.28) to ($7.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TFF Pharmaceuticals is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TFF Pharmaceuticals is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TFF Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad StockEarnings

Your eBook: Mastering Earnings Announcements Trading

Trading around earnings announcements (Pre-Earnings, Into-Earnings, and Post-Earnings) provides a unique trading opportunity. That is because trading around earnings announcements presents short-term trading opportunities (these are great because they don’t tie your money up for very long).

Click Here to Claim Your FREE The Ultimate Strategy Guide To Trade Earnings E-Book .

About TFF Pharmaceuticals Stock (NASDAQ:TFFP)

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

TFFP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TFFP Stock News Headlines

April 15, 2024 | markets.businessinsider.com

TFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation Powder

April 15, 2024 | globenewswire.com

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

April 1, 2024 | finance.yahoo.com

TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

March 29, 2024 | investing.com

TFF Pharmaceuticals reports positive phase 2 trial results

March 29, 2024 | finanznachrichten.de

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

March 28, 2024 | investorplace.com

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023

March 28, 2024 | globenewswire.com

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 27, 2024 | globenewswire.com

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

March 25, 2024 | globenewswire.com

TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting

March 22, 2024 | globenewswire.com

TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 21, 2024 | finance.yahoo.com

TFF Pharmaceuticals, Inc. (TFFP)

March 20, 2024 | globenewswire.com

TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 20, 2024 | globenewswire.com

TFF Pharmaceuticals Announces Update on Clinical Programs

March 14, 2024 | globenewswire.com

TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024

March 12, 2024 | uk.investing.com

Tff Pharmaceuticals Inc (TFFP)

January 24, 2024 | finance.yahoo.com

TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference

January 9, 2024 | finance.yahoo.com

TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting

January 5, 2024 | morningstar.com

TFF Pharmaceuticals Inc Ordinary Shares

December 21, 2023 | markets.businessinsider.com

Positive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price Target

December 19, 2023 | finanznachrichten.de

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

December 19, 2023 | markets.businessinsider.com

TFF Pharma Reveals Positive Initial Data From Ongoing Phase 2 Trials Of TFF VORI And TFF TAC

December 19, 2023 | finance.yahoo.com

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

December 18, 2023 | finance.yahoo.com

TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC

December 15, 2023 | markets.businessinsider.com

TFF Declares Reverse Stock Split For 1 Post-split Share For Every 25 Pre-split Shares

December 15, 2023 | finance.yahoo.com

TFF Pharmaceuticals Announces Reverse Stock Split

See More Headlines

Receive TFFP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TFF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/15/2023
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TFFP
CUSIP: N/A
CIK: 1733413
Web: www.tffpharma.com
Phone: 817-438-6168
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $72.00
High Stock Price Target: $100.00
Low Stock Price Target: $44.00
Potential Upside/Downside: +2,081.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($12.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,240,000.00
Net Margins: -2,897.95%
Pretax Margin: -2,894.14%
Return on Equity: -163.14%
Return on Assets: -144.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.12
Quick Ratio: 3.12

Sales & Book Value

Annual Sales: $730,000.00
Price / Sales: 11.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.04 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 2,520,000
Free Float: 2,378,000
Market Cap: $8.32 million
Optionable: Optionable
Beta: 1.29

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Harlan F. Weisman (Age 72)
President, CEO & Director
Comp: $594.48k
Mr. Kirk Allen Coleman (Age 50)
CFO, Treasurer & Secretary
Comp: $382.22k
Dr. Zamaneh Mikhak M.D. (Age 60)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TFFP Stock Analysis - Frequently Asked Questions

Should I buy or sell TFF Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TFF Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TFFP shares.
View TFFP analyst ratings or view top-rated stocks.
What is TFF Pharmaceuticals' stock price target for 2024?: 1 brokers have issued 1-year price targets for TFF Pharmaceuticals' shares. Their TFFP share price targets range from $44.00 to $100.00. On average, they expect the company's share price to reach $72.00 in the next year. This suggests a possible upside of 2,049.3% from the stock's current price.
View analysts price targets for TFFP or view top-rated stocks among Wall Street analysts.
How have TFFP shares performed in 2024?: TFF Pharmaceuticals' stock was trading at $7.02 at the beginning of the year. Since then, TFFP shares have decreased by 52.3% and is now trading at $3.35.
View the best growth stocks for 2024 here.
Are investors shorting TFF Pharmaceuticals?: TFF Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 86,600 shares, an increase of 86.6% from the March 15th total of 46,400 shares. Based on an average trading volume of 28,500 shares, the days-to-cover ratio is presently 3.0 days. Approximately 3.4% of the shares of the stock are sold short.
View TFF Pharmaceuticals' Short Interest.
When is TFF Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TFFP earnings forecast.
How were TFF Pharmaceuticals' earnings last quarter?: TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) issued its quarterly earnings data on Tuesday, August, 15th. The company reported ($3.50) earnings per share for the quarter, topping analysts' consensus estimates of ($5.00) by $1.50. The business had revenue of $0.33 million for the quarter, compared to analysts' expectations of $0.10 million. TFF Pharmaceuticals had a negative net margin of 2,897.95% and a negative trailing twelve-month return on equity of 163.14%. During the same quarter in the prior year, the company earned ($8.50) earnings per share.

When did TFF Pharmaceuticals' stock split?: TFF Pharmaceuticals shares reverse split on Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of TFF Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other TFF Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), VYNE Therapeutics (VYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), Chimerix (CMRX) and DURECT (DRRX).
When did TFF Pharmaceuticals IPO?: TFF Pharmaceuticals (TFFP) raised $22 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 4,400,000 shares at a price of $5.00 per share. National Securities acted as the underwriter for the IPO.
How do I buy shares of TFF Pharmaceuticals?: Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TFFP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial